Evidence map›Paper›PMID 42745547›Full record

ArticleBioinformatics (Oxford, England)2026

scBalFlow: a staged flow matching framework for imbalanced single-cell drug perturbation prediction.

Hanwen Lyu, Jiawei Luo

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hanwen LyuCollege of Computer Science and Electronic Engineering, Hunan University, Hunan 410082, China.ORCID 0009-0006-0046-7876
Jiawei LuoCollege of Computer Science and Electronic Engineering, Hunan University, Hunan 410082, China.ORCID 0000-0003-2385-8272

Funding

National Natural Science Foundation of China 62372165
6 · The paper itself

Abstract

motivationConventional drug perturbation prediction models typically employ end-to-end encoder-decoder architectures, directly mapping control samples and perturbation conditions to post-perturbation gene expression profiles. However, these approaches widely overlook the severe class imbalance inherent in perturbation datasets, leading to a predictive bias toward weakly responsive samples.

resultsTo address this bottleneck, we propose scBalFlow, a decoupled two-stage training framework. The first stage predicts the perturbation response intensity under given conditions, employing a Gaussian-Augmented Inference (GAI) strategy to counteract data imbalance. Crucially, the second stage bypasses weakly responsive conditions, while utilizing a Flow Matching model to synthesize highly responsive samples. Comprehensive evaluations on large-scale benchmarks, including SciPlex3 and McFarland, demonstrate that scBalFlow effectively overcomes the imbalance issue and significantly outperforms existing state-of-the-art methods on imbalanced datasets, particularly in capturing complex distribution shifts and maintaining single-cell distributional consistency. AVAILABILITY AND IMPLEMENTATION: The source code and datasets are available at GitHub https://github.com/hanwenlv-cmd/scBalFlow and Figshare with doi:10.6084/m9.figshare.33137447. The datasets of SciPlex3, ComboSciPlex, and McFarland underlying this study are available via the pertpy package. Alternatively, they can be downloaded manually from https://exampledata.scverse.org/pertpy/srivatsan_2020_sciplex3.h5ad for SciPlex3, https://exampledata.scverse.org/pertpy/combosciplex.h5ad for combosciplex, and https://exampledata.scverse.org/pertpy/mcfarland_2020.h5ad for McFarland.

Indexed as

Computational BiologySingle-Cell AnalysisSoftwareAlgorithmsHumans

Identifiers

PMID42745547
PMCPMC13619003

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.